# pathway_0025: before and after transfer clarification

[All 1,328 cases](../README.md) · [Method](../METHOD.md) · [Summary](../SUMMARY.md) · [Exact reviewer user message](../inputs/pathway_0025.txt)

**Task:** `pathway`  
**Author key, unchanged:** **B** — Secondary metabolite biosynthesis. .

| Round | Reviewer | Key support | Transfer / lookup | Output usability (canonical status) |
|---|---|---|---|---|
| before | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| before | Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | usable output (valid_review) |
| after | GPT-6 Luna | supported | reasoning-supported | usable output (valid_review) |
| after | Qwen3.8-Flash-Next-NVFP4 | no saved label | no saved label | output error (invalid_review) |

**Usable output means format-valid review, not reasoning-supported or biologically correct.** A usable output can classify the question as reasoning-supported, lookup-dependent or uncertain. An output error is a problem with the saved model response; it does not count a defective benchmark question or wrong key. Each saved review is retained in full below. Labels from output errors are displayed as saved and excluded from label statistics. The author key and reviewer evidence were visible to reviewers; this is a review of answerability and key support, not a benchmark-solving score.

## Complete original question

```text
[Protein Sequence]
MPSHTFNPQAGYDLAVDRNLGLGEIFYNRAQKSHQAIAVCDGGAVLTYGQLHAKAYRLAQELSQWLRLTEKPVGIVVQHGMADVVAQMAVIYAGGSCAPMDPTLPDNQIQGRLKRLDAVCVLTDQANRHRDLGADVLCIDDFDIADLAPEDTLYPVATNLEHCAYLIHTSGTTAEPKAVQIAARSILHVAFYAPLEPVYDTDVVAHANNSSFDVSLFDIWVPLLRGAQIAVINKAVLLDPPMMAREIDRLGITVMATTTAVLNLAAFIYPKAFAKLRLVTIGGEAANVAAIRIILKNGPPAMLFNAYGPTECCVFCLAHQITPADVEHGSIGVSIGKPVGRTITYIAGDEGGESDQGELWIGGPGVSPGYFRQPEKNLAAFSDLGEAMTSLENPVRFYRTGDIVRRRPNGALEYVGRRDHQVKVRGFRIELEAVEAGLLKTGLFSDAVAMRIEMPQNGAGSILAAYVVPTDVSKPPTMDEALESAKSILPHYMVPQLELVPRLPLNRHLKVDRKQLAELFGRRWEDVSPAQPENASQDVRSALVSLWATVLASPLSTYGDDDDFLHLGGTSLQAAMLINQIRHKFDIEVSLLTLYDNTTLGALTSIIKQRLSGQSETLHNEKDSWVADSEIADDLSCPLDRPIDWCRDTEGRVFLTGGTGFVGAFLLADLLHMPQTSQVRCLVRATDAAVGQERLRAALDKYGLWEDGFADKLVAIAGLLEDDYLGMGREQFEEAASWASVVFHLGARVNYAQPYSLHRASNTLGTRNMVRFACAGRTKAIHYVSSIGCFGPTGSILGTTSVREDEPLLPHITALPYDHGYAQSQWVADALLRRLMDRGFPIAIYRPGFIVGHSQTGACNPDDFLSRLIDACREIGCYPQLPNQRKEFVPVDYVNAAILHIAASPASLGHAYHIVPPTRAVSIDMDNSMALVDRAGNSPMRPVSYKEWVERLAATSPKRLLPLQPMLAERVKDGLTRWELYENMPVYETTNTARALQNYPGGLQFPVLDTSLMKRYLDFLEAKG

[Multiple Choices]
A. L-threonine from L-aspartate: step 5/5. .
B. Secondary metabolite biosynthesis. .
C. L-valine biosynthesis
D. L-methionine biosynthesis via de novo pathway. .
```

<details>
<summary>Complete original system instructions</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## Four saved visible reviews

## Before: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The exact sequence matches the UniProt record for FrzA, which annotates its pathway as secondary metabolite biosynthesis and cites a study on FR901483 biosynthesis. The annotation carries experimental-evidence code ECO:0000269, though the primary paper was not independently reviewed here.

Citations as saved: [H3](#evidence-h3), [H2](#evidence-h2), [C5](#evidence-c5), [C6](#evidence-c6).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence is a long fungal enzyme, but its length and general sequence features do not meaningfully distinguish a role in secondary-metabolite biosynthesis from the listed amino-acid biosynthesis pathways.


**Missing item-specific fact**

> The protein-specific identification and functional assignment of FrzA to the FR901483 biosynthetic pathway are absent from the input.


**Reason**

> Selecting B depends on knowing this protein's specific function or pathway annotation; recognizing the sequence or relying on a generic sequence heuristic would not provide that information.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The supplied evidence supports B; the other choices name specific amino-acid biosynthesis pathways and are not supported for this protein by the available record.


### Important caveats

- The reviewer-only database evidence confirms a sequence match but was not available to the evaluated model.
- The author’s exact source snapshot is unknown; the historical record also matches the sequence and contains the pathway annotation.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is a long fungal enzyme, but its length and general sequence features do not meaningfully distinguish a role in secondary-metabolite biosynthesis from the listed amino-acid biosynthesis pathways.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein-specific identification and functional assignment of FrzA to the FR901483 biosynthetic pathway are absent from the input.",
    "reason": "Selecting B depends on knowing this protein's specific function or pathway annotation; recognizing the sequence or relying on a generic sequence heuristic would not provide that information."
  },
  "case_id": "pathway_0025",
  "expected_answer_check": {
    "evidence_ids": [
      "H3",
      "H2",
      "C5",
      "C6"
    ],
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt record for FrzA, which annotates its pathway as secondary metabolite biosynthesis and cites a study on FR901483 biosynthesis. The annotation carries experimental-evidence code ECO:0000269, though the primary paper was not independently reviewed here."
  },
  "important_caveats": [
    "The reviewer-only database evidence confirms a sequence match but was not available to the evaluated model.",
    "The author’s exact source snapshot is unknown; the historical record also matches the sequence and contains the pathway annotation."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The supplied evidence supports B; the other choices name specific amino-acid biosynthesis pathways and are not supported for this protein by the available record."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0025",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt record for FrzA, which annotates its pathway as secondary metabolite biosynthesis and cites a study on FR901483 biosynthesis. The annotation carries experimental-evidence code ECO:0000269, though the primary paper was not independently reviewed here.",
    "evidence_ids": ["H3", "H2", "C5", "C6"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence is a long fungal enzyme, but its length and general sequence features do not meaningfully distinguish a role in secondary-metabolite biosynthesis from the listed amino-acid biosynthesis pathways.",
    "missing_item_specific_fact": "The protein-specific identification and functional assignment of FrzA to the FR901483 biosynthetic pathway are absent from the input.",
    "reason": "Selecting B depends on knowing this protein's specific function or pathway annotation; recognizing the sequence or relying on a generic sequence heuristic would not provide that information."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The supplied evidence supports B; the other choices name specific amino-acid biosynthesis pathways and are not supported for this protein by the available record."
  },
  "important_caveats": [
    "The reviewer-only database evidence confirms a sequence match but was not available to the evaluated model.",
    "The author’s exact source snapshot is unknown; the historical record also matches the sequence and contains the pathway annotation."
  ]
}
```

</details>

## Before: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> UniProt entry A0A7T8F1L4 annotates this protein as 'Non-canonical nonribosomal peptide synthetase FrzA' (EC 1.2.1.101) with pathway 'Secondary metabolite biosynthesis' supported by experimental evidence (ECO:0000269, PubMed:33372776). The protein is part of the FR901483 immunosuppressant biosynthesis cluster in Cladobotryum sp., a fungal secondary metabolite. The sequence matches exactly (SHA-256 confirmed).

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H1](#evidence-h1), [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The 1024-aa sequence exhibits unmistakable multi-domain NRPS architecture: a PCP domain with the conserved 'GGSC' phosphopantetheinylation serine motif, adenylation (A) domain signatures (including 'GGxxxDG' and 'GELWIGGPGVSPGYFRQPEKNLAAFSDLGEAMTSLENPVRFYRTGDIVRRRPNGALEYVGRRDHQVKVRGFRIELEAVEAGLLKTGLFSDAVAMRIEMPQNGAGSILAAYVVPTDVSKPPTMDEALESAKSILPHYMVPQLELVPRLPLNRHLKVDRKQLAELFGRRWEDVSPAQPENASQDVRSALVSLWATVLASPLSTYGDDDDFLHLGGTSLQAAMLINQIRHKFDIEVSLLTLYDNTTLGALTSIIKQRLSGQSETLHNEKDSWVADSEIADDLSCPLDRPIDWCRDTEGRVFLTGGTGFVGAFLLADLLHMPQTSQVRCLVRATDAAVGQERLRAALDKYGLWEDGFADKLVAIAGLLEDDYLGMGREQFEEAASWASVVFHLGARVNYAQPYSLHRASNTLGTRNMVRFACAGRTKAIHYVSSIGCFGPTGSILGTTSVREDEPLLPHITALPYDHGYAQSQWVADALLRRLMDRGFPIAIYRPGFIVGHSQTGACNPDDFLSRLIDACREIGCYPQLPNQRKEFVPVDYVNAAILHIAASPASLGHAYHIVPPTRAVSIDMDNSMALVDRAGNSPMRPVSYKEWVERLAATSPKRLLPLQPMLAERVKDGLTRWELYENMPVYETTNTARALQNYPGGLQFPVLDTSLMKRYLDFLEAKG' patterns), a condensation (C) domain with 'HHxxxDG' motif, and a terminal reductase (R) domain with NAD(P)-binding 'GxGxxG' pattern. NRPS enzymes are by definition dedicated to secondary metabolite (e.g., antibiotic, immunosuppressant, siderophore) biosynthesis and are never involved in primary amino acid biosynthesis. The distractors (threonine, valine, methionine biosynthesis) are primary metabolic pathways catalyzed by small monofunctional enzymes (~200-400 aa), incompatible with a 1024-aa multi-domain NRPS.


**Missing item-specific fact**

> None required. Recognition of NRPS domain architecture from sequence motifs and the general biological principle that NRPS enzymes produce secondary metabolites is sufficient to select B over the primary amino acid biosynthesis distractors.


**Reason**

> A model with knowledge of NRPS domain signatures (PCP 'GGSC' serine, C-domain 'HHxxxDG', A-domain core motifs, terminal reductase) can identify the protein as a non-ribosomal peptide synthetase from the sequence alone. The fundamental biological fact that NRPS enzymes exclusively participate in secondary metabolite biosynthesis—not primary amino acid metabolism—allows elimination of all three distractors without needing to know the specific FR901483 pathway or the protein's exact name.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The NRPS architecture is unambiguous and incompatible with primary amino acid biosynthesis pathways (A, C, D). Only option B (Secondary metabolite biosynthesis) is consistent with a multi-domain NRPS enzyme. No other choice is defensible.


### Important caveats

- The UniProt annotation carries experimental evidence (ECO:0000269, direct assay from PubMed:33372776), not merely computational inference.
- The entry was first public in June 2025; the author's source snapshot date is unknown, though the sequence has been stable since 2021.
- The term 'non-canonical' in the protein name refers to unusual NRPS domain organization (lacking a TE domain, using a reductase instead), not to a different pathway class.
- The question asks for the 'primary pathway'—the UniProt pathway comment states 'Secondary metabolite biosynthesis' without further specificity, matching option B verbatim.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The 1024-aa sequence exhibits unmistakable multi-domain NRPS architecture: a PCP domain with the conserved 'GGSC' phosphopantetheinylation serine motif, adenylation (A) domain signatures (including 'GGxxxDG' and 'GELWIGGPGVSPGYFRQPEKNLAAFSDLGEAMTSLENPVRFYRTGDIVRRRPNGALEYVGRRDHQVKVRGFRIELEAVEAGLLKTGLFSDAVAMRIEMPQNGAGSILAAYVVPTDVSKPPTMDEALESAKSILPHYMVPQLELVPRLPLNRHLKVDRKQLAELFGRRWEDVSPAQPENASQDVRSALVSLWATVLASPLSTYGDDDDFLHLGGTSLQAAMLINQIRHKFDIEVSLLTLYDNTTLGALTSIIKQRLSGQSETLHNEKDSWVADSEIADDLSCPLDRPIDWCRDTEGRVFLTGGTGFVGAFLLADLLHMPQTSQVRCLVRATDAAVGQERLRAALDKYGLWEDGFADKLVAIAGLLEDDYLGMGREQFEEAASWASVVFHLGARVNYAQPYSLHRASNTLGTRNMVRFACAGRTKAIHYVSSIGCFGPTGSILGTTSVREDEPLLPHITALPYDHGYAQSQWVADALLRRLMDRGFPIAIYRPGFIVGHSQTGACNPDDFLSRLIDACREIGCYPQLPNQRKEFVPVDYVNAAILHIAASPASLGHAYHIVPPTRAVSIDMDNSMALVDRAGNSPMRPVSYKEWVERLAATSPKRLLPLQPMLAERVKDGLTRWELYENMPVYETTNTARALQNYPGGLQFPVLDTSLMKRYLDFLEAKG' patterns), a condensation (C) domain with 'HHxxxDG' motif, and a terminal reductase (R) domain with NAD(P)-binding 'GxGxxG' pattern. NRPS enzymes are by definition dedicated to secondary metabolite (e.g., antibiotic, immunosuppressant, siderophore) biosynthesis and are never involved in primary amino acid biosynthesis. The distractors (threonine, valine, methionine biosynthesis) are primary metabolic pathways catalyzed by small monofunctional enzymes (~200-400 aa), incompatible with a 1024-aa multi-domain NRPS.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "None required. Recognition of NRPS domain architecture from sequence motifs and the general biological principle that NRPS enzymes produce secondary metabolites is sufficient to select B over the primary amino acid biosynthesis distractors.",
    "reason": "A model with knowledge of NRPS domain signatures (PCP 'GGSC' serine, C-domain 'HHxxxDG', A-domain core motifs, terminal reductase) can identify the protein as a non-ribosomal peptide synthetase from the sequence alone. The fundamental biological fact that NRPS enzymes exclusively participate in secondary metabolite biosynthesis—not primary amino acid metabolism—allows elimination of all three distractors without needing to know the specific FR901483 pathway or the protein's exact name."
  },
  "case_id": "pathway_0025",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "C6",
      "H1",
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "UniProt entry A0A7T8F1L4 annotates this protein as 'Non-canonical nonribosomal peptide synthetase FrzA' (EC 1.2.1.101) with pathway 'Secondary metabolite biosynthesis' supported by experimental evidence (ECO:0000269, PubMed:33372776). The protein is part of the FR901483 immunosuppressant biosynthesis cluster in Cladobotryum sp., a fungal secondary metabolite. The sequence matches exactly (SHA-256 confirmed)."
  },
  "important_caveats": [
    "The UniProt annotation carries experimental evidence (ECO:0000269, direct assay from PubMed:33372776), not merely computational inference.",
    "The entry was first public in June 2025; the author's source snapshot date is unknown, though the sequence has been stable since 2021.",
    "The term 'non-canonical' in the protein name refers to unusual NRPS domain organization (lacking a TE domain, using a reductase instead), not to a different pathway class.",
    "The question asks for the 'primary pathway'—the UniProt pathway comment states 'Secondary metabolite biosynthesis' without further specificity, matching option B verbatim."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The NRPS architecture is unambiguous and incompatible with primary amino acid biosynthesis pathways (A, C, D). Only option B (Secondary metabolite biosynthesis) is consistent with a multi-domain NRPS enzyme. No other choice is defensible."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0025",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "UniProt entry A0A7T8F1L4 annotates this protein as 'Non-canonical nonribosomal peptide synthetase FrzA' (EC 1.2.1.101) with pathway 'Secondary metabolite biosynthesis' supported by experimental evidence (ECO:0000269, PubMed:33372776). The protein is part of the FR901483 immunosuppressant biosynthesis cluster in Cladobotryum sp., a fungal secondary metabolite. The sequence matches exactly (SHA-256 confirmed).",
    "evidence_ids": ["C4", "C5", "C6", "H1", "H2", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The 1024-aa sequence exhibits unmistakable multi-domain NRPS architecture: a PCP domain with the conserved 'GGSC' phosphopantetheinylation serine motif, adenylation (A) domain signatures (including 'GGxxxDG' and 'GELWIGGPGVSPGYFRQPEKNLAAFSDLGEAMTSLENPVRFYRTGDIVRRRPNGALEYVGRRDHQVKVRGFRIELEAVEAGLLKTGLFSDAVAMRIEMPQNGAGSILAAYVVPTDVSKPPTMDEALESAKSILPHYMVPQLELVPRLPLNRHLKVDRKQLAELFGRRWEDVSPAQPENASQDVRSALVSLWATVLASPLSTYGDDDDFLHLGGTSLQAAMLINQIRHKFDIEVSLLTLYDNTTLGALTSIIKQRLSGQSETLHNEKDSWVADSEIADDLSCPLDRPIDWCRDTEGRVFLTGGTGFVGAFLLADLLHMPQTSQVRCLVRATDAAVGQERLRAALDKYGLWEDGFADKLVAIAGLLEDDYLGMGREQFEEAASWASVVFHLGARVNYAQPYSLHRASNTLGTRNMVRFACAGRTKAIHYVSSIGCFGPTGSILGTTSVREDEPLLPHITALPYDHGYAQSQWVADALLRRLMDRGFPIAIYRPGFIVGHSQTGACNPDDFLSRLIDACREIGCYPQLPNQRKEFVPVDYVNAAILHIAASPASLGHAYHIVPPTRAVSIDMDNSMALVDRAGNSPMRPVSYKEWVERLAATSPKRLLPLQPMLAERVKDGLTRWELYENMPVYETTNTARALQNYPGGLQFPVLDTSLMKRYLDFLEAKG' patterns), a condensation (C) domain with 'HHxxxDG' motif, and a terminal reductase (R) domain with NAD(P)-binding 'GxGxxG' pattern. NRPS enzymes are by definition dedicated to secondary metabolite (e.g., antibiotic, immunosuppressant, siderophore) biosynthesis and are never involved in primary amino acid biosynthesis. The distractors (threonine, valine, methionine biosynthesis) are primary metabolic pathways catalyzed by small monofunctional enzymes (~200-400 aa), incompatible with a 1024-aa multi-domain NRPS.",
    "missing_item_specific_fact": "None required. Recognition of NRPS domain architecture from sequence motifs and the general biological principle that NRPS enzymes produce secondary metabolites is sufficient to select B over the primary amino acid biosynthesis distractors.",
    "reason": "A model with knowledge of NRPS domain signatures (PCP 'GGSC' serine, C-domain 'HHxxxDG', A-domain core motifs, terminal reductase) can identify the protein as a non-ribosomal peptide synthetase from the sequence alone. The fundamental biological fact that NRPS enzymes exclusively participate in secondary metabolite biosynthesis—not primary amino acid metabolism—allows elimination of all three distractors without needing to know the specific FR901483 pathway or the protein's exact name."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The NRPS architecture is unambiguous and incompatible with primary amino acid biosynthesis pathways (A, C, D). Only option B (Secondary metabolite biosynthesis) is consistent with a multi-domain NRPS enzyme. No other choice is defensible."
  },
  "important_caveats": [
    "The UniProt annotation carries experimental evidence (ECO:0000269, direct assay from PubMed:33372776), not merely computational inference.",
    "The entry was first public in June 2025; the author's source snapshot date is unknown, though the sequence has been stable since 2021.",
    "The term 'non-canonical' in the protein name refers to unusual NRPS domain organization (lacking a TE domain, using a reductase instead), not to a different pathway class.",
    "The question asks for the 'primary pathway'—the UniProt pathway comment states 'Secondary metabolite biosynthesis' without further specificity, matching option B verbatim."
  ]
}
```

</details>

## After: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence matches the source record, whose pathway annotation is “Secondary metabolite biosynthesis” and carries an experimental-evidence code citing the FR901483 biosynthesis study. This supports choice B, though the cited study was not independently reviewed here.

Citations as saved: [C5](#evidence-c5), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The supplied sequence is unusually long (about 1,024 residues) and has the appearance of a large, multi-region biosynthetic enzyme rather than a typical single-step enzyme in primary amino-acid synthesis. Transferable knowledge that large fused or multidomain enzymes are common in specialized-metabolite biosynthesis makes B a meaningful choice over the offered threonine, valine, and methionine biosynthesis pathways.


**Missing item-specific fact**

Empty string, as saved.


**Reason**

> The sequence’s size and apparent multi-region architecture provide a probabilistic distinction among these particular choices without requiring recall of this protein’s database annotation. The inference is not a definitive pathway assignment, but the alternatives are sufficiently different for it to support B.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The three alternatives naming specific amino-acid biosynthesis pathways are less consistent with the sequence’s large, complex architecture than the broad secondary-metabolite option.


### Important caveats

- The sequence-based argument is suggestive, not experimental proof; a large protein could in principle participate in primary metabolism.
- The pathway annotation supports the key, but its cited study was not independently validated in this review.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The supplied sequence is unusually long (about 1,024 residues) and has the appearance of a large, multi-region biosynthetic enzyme rather than a typical single-step enzyme in primary amino-acid synthesis. Transferable knowledge that large fused or multidomain enzymes are common in specialized-metabolite biosynthesis makes B a meaningful choice over the offered threonine, valine, and methionine biosynthesis pathways.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "",
    "reason": "The sequence’s size and apparent multi-region architecture provide a probabilistic distinction among these particular choices without requiring recall of this protein’s database annotation. The inference is not a definitive pathway assignment, but the alternatives are sufficiently different for it to support B."
  },
  "case_id": "pathway_0025",
  "expected_answer_check": {
    "evidence_ids": [
      "C5",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The sequence matches the source record, whose pathway annotation is “Secondary metabolite biosynthesis” and carries an experimental-evidence code citing the FR901483 biosynthesis study. This supports choice B, though the cited study was not independently reviewed here."
  },
  "important_caveats": [
    "The sequence-based argument is suggestive, not experimental proof; a large protein could in principle participate in primary metabolism.",
    "The pathway annotation supports the key, but its cited study was not independently validated in this review."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The three alternatives naming specific amino-acid biosynthesis pathways are less consistent with the sequence’s large, complex architecture than the broad secondary-metabolite option."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0025",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence matches the source record, whose pathway annotation is “Secondary metabolite biosynthesis” and carries an experimental-evidence code citing the FR901483 biosynthesis study. This supports choice B, though the cited study was not independently reviewed here.",
    "evidence_ids": ["C5", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The supplied sequence is unusually long (about 1,024 residues) and has the appearance of a large, multi-region biosynthetic enzyme rather than a typical single-step enzyme in primary amino-acid synthesis. Transferable knowledge that large fused or multidomain enzymes are common in specialized-metabolite biosynthesis makes B a meaningful choice over the offered threonine, valine, and methionine biosynthesis pathways.",
    "missing_item_specific_fact": "",
    "reason": "The sequence’s size and apparent multi-region architecture provide a probabilistic distinction among these particular choices without requiring recall of this protein’s database annotation. The inference is not a definitive pathway assignment, but the alternatives are sufficiently different for it to support B."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The three alternatives naming specific amino-acid biosynthesis pathways are less consistent with the sequence’s large, complex architecture than the broad secondary-metabolite option."
  },
  "important_caveats": [
    "The sequence-based argument is suggestive, not experimental proof; a large protein could in principle participate in primary metabolism.",
    "The pathway annotation supports the key, but its cited study was not independently validated in this review."
  ]
}
```

</details>

## After: Qwen3.8-Flash-Next-NVFP4

**Output usability:** output error.
**Canonical saved status:** `invalid_review`.

**This saved response has an output error and is not a usable structured review.** Any labels below remain the original saved values; they are excluded from label distributions and agreement. This output status does not judge the benchmark question, author key or biological correctness. No field or option ID has been repaired.

No visible final review text was saved. Internal model reasoning is not a substitute for a visible review and is not published. The final-content extraction failed because the saved final content was not text.

**Saved parsed visible review:** `null`.

**Exact saved visible final text:** empty string (`""`). No visible final is synthesized from private reasoning.

## Existing project source checks of the old Luna review only

These unchanged notes concern the earlier Luna claims. They do not validate either new review or the old Qwen review. No new scientific adjudication was performed.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Complete reviewer-only evidence and qualifications

All excerpts supplied in the original and revised reviewer user message follow. This material was not available to the original evaluated model. Accession identity came from dataset image-path metadata. Source support and transferable discrimination are separate judgments.

**Applicability metadata, unchanged:**

```json
{
  "requested_accession": "A0A7T8F1L4",
  "identity_origin": "reviewer-only accession inferred mechanically from original dataset image-path metadata; this accession/metadata was absent from evaluated model input",
  "benchmark_sequence_sha256": "78903b102e2259d837b80ac44bcf15e6ae1534722167cff1a23d530bb0db74e0",
  "benchmark_sequence_length": 1024,
  "current_status": "retrieved",
  "current_sequence_comparison": "matched",
  "current_entry_audit": {
    "entryVersion": 20,
    "firstPublicDate": "2025-06-18",
    "lastAnnotationUpdateDate": "2026-09-02",
    "lastSequenceUpdateDate": "2021-06-02",
    "sequenceVersion": 1
  },
  "current_uniprot_release": "2026_03",
  "current_record_sha256": "4cf4e4af61e7d91300bdd1c46dcd31d2e7126d4631315e40df3061127135d0fb",
  "current_source_sequence_sha256": "78903b102e2259d837b80ac44bcf15e6ae1534722167cff1a23d530bb0db74e0",
  "current_source_sequence_length": 1024,
  "historical_status": "retrieved",
  "historical_cutoff_date": "2026-05-07",
  "historical_sequence_comparison": "matched",
  "selected_historical_entry_version": 18,
  "selected_historical_version": {
    "accession": "A0A7T8F1L4",
    "database": "Swiss-Prot",
    "entryVersion": 18,
    "firstRelease": "2026_01/2026_01",
    "firstReleaseDate": "28-Jan-2026",
    "lastRelease": "2026_01/2026_01",
    "lastReleaseDate": "28-Jan-2026",
    "name": "FRZA_CLASX",
    "sequenceVersion": 1
  },
  "selected_historical_record_sha256": "dc244e3d4206d7a97707ec88200b44521e519f3504ebcf6f0cd7d074b3fd2c4b",
  "selected_historical_source_sequence_sha256": "78903b102e2259d837b80ac44bcf15e6ae1534722167cff1a23d530bb0db74e0",
  "selected_historical_source_sequence_length": 1024,
  "latest_at_cutoff_sequence_comparison": "matched",
  "historical_sequence_versions_checked": [
    {
      "entry_version": 18,
      "exact_sequence_comparison": "matched",
      "sequence_version": 1
    }
  ],
  "actual_author_source_snapshot": "unknown",
  "numbering": "Canonical entry coordinates; construct or isoform numbering is not assumed."
}
```

**Qualifications, unchanged:**

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json)

```json
{
  "evidence_id": "C1",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json",
  "source_sha256": "4cf4e4af61e7d91300bdd1c46dcd31d2e7126d4631315e40df3061127135d0fb",
  "retrieved_utc": "2026-11-02T04:25:48.509506+00:00",
  "json_pointer": "/primaryAccession",
  "excerpt": "\"A0A7T8F1L4\"",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C2

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json)

```json
{
  "evidence_id": "C2",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json",
  "source_sha256": "4cf4e4af61e7d91300bdd1c46dcd31d2e7126d4631315e40df3061127135d0fb",
  "retrieved_utc": "2026-11-02T04:25:48.509506+00:00",
  "json_pointer": "/entryAudit",
  "excerpt": "{\"entryVersion\":20,\"firstPublicDate\":\"2025-06-18\",\"lastAnnotationUpdateDate\":\"2026-09-02\",\"lastSequenceUpdateDate\":\"2021-06-02\",\"sequenceVersion\":1}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C3

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json)

```json
{
  "evidence_id": "C3",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json",
  "source_sha256": "4cf4e4af61e7d91300bdd1c46dcd31d2e7126d4631315e40df3061127135d0fb",
  "retrieved_utc": "2026-11-02T04:25:48.509506+00:00",
  "json_pointer": "/organism",
  "excerpt": "{\"lineage\":[\"Eukaryota\",\"Fungi\",\"Dikarya\",\"Ascomycota\",\"Pezizomycotina\",\"Sordariomycetes\",\"Hypocreomycetidae\",\"Hypocreales\",\"Hypocreaceae\",\"Cladobotryum\"],\"scientificName\":\"Cladobotryum sp\",\"taxonId\":2040732}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json)

```json
{
  "evidence_id": "C4",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json",
  "source_sha256": "4cf4e4af61e7d91300bdd1c46dcd31d2e7126d4631315e40df3061127135d0fb",
  "retrieved_utc": "2026-11-02T04:25:48.509506+00:00",
  "json_pointer": "/proteinDescription",
  "excerpt": "{\"alternativeNames\":[{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"FR901483 biosynthesis cluster protein A\"}}],\"recommendedName\":{\"ecNumbers\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000269\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"1.2.1.101\"}],\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"Non-canonical nonribosomal peptide synthetase FrzA\"}}}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json)

```json
{
  "evidence_id": "C5",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json",
  "source_sha256": "4cf4e4af61e7d91300bdd1c46dcd31d2e7126d4631315e40df3061127135d0fb",
  "retrieved_utc": "2026-11-02T04:25:48.509506+00:00",
  "json_pointer": "/comments/3",
  "excerpt": "{\"commentType\":\"PATHWAY\",\"texts\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000269\",\"id\":\"33372776\",\"source\":\"PubMed\"}],\"value\":\"Secondary metabolite biosynthesis\"}]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json)

```json
{
  "evidence_id": "C6",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A7T8F1L4.json",
  "source_sha256": "4cf4e4af61e7d91300bdd1c46dcd31d2e7126d4631315e40df3061127135d0fb",
  "retrieved_utc": "2026-11-02T04:25:48.509506+00:00",
  "json_pointer": "/references/0",
  "excerpt": "{\"citation\":{\"authors\":[\"Zhang Z.\",\"Tamura Y.\",\"Tang M.\",\"Qiao T.\",\"Sato M.\",\"Otsu Y.\",\"Sasamura S.\",\"Taniguchi M.\",\"Watanabe K.\",\"Tang Y.\"],\"citationCrossReferences\":[{\"database\":\"PubMed\",\"id\":\"33372776\"},{\"database\":\"DOI\",\"id\":\"10.1021/jacs.0c12352\"}],\"citationType\":\"journal article\",\"firstPage\":\"132\",\"id\":\"33372776\",\"journal\":\"J. Am. Chem. Soc.\",\"lastPage\":\"136\",\"publicationDate\":\"2021\",\"title\":\"Biosynthesis of the Immunosuppressant (-)-FR901483.\",\"volume\":\"143\"},\"referenceComments\":[{\"type\":\"STRAIN\",\"value\":\"11231\"}],\"referenceNumber\":1,\"referencePositions\":[\"NUCLEOTIDE SEQUENCE [GENOMIC DNA]\",\"FUNCTION\",\"CATALYTIC ACTIVITY\",\"PATHWAY\"]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8F1L4?format=txt&versions=18)

```json
{
  "evidence_id": "H1",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A7T8F1L4?format=txt&versions=18",
  "source_sha256": "dc244e3d4206d7a97707ec88200b44521e519f3504ebcf6f0cd7d074b3fd2c4b",
  "retrieved_utc": "2026-11-02T04:25:50.375049+00:00",
  "source_locator": "lines 1-13",
  "excerpt": "ID   FRZA_CLASX              Reviewed;        1024 AA.\nAC   A0A7T8F1L4;\nDT   18-JUN-2025, integrated into UniProtKB/Swiss-Prot.\nDT   02-JUN-2021, sequence version 1.\nDT   28-JAN-2026, entry version 18.\nDE   RecName: Full=Non-canonical nonribosomal peptide synthetase FrzA {ECO:0000303|PubMed:33372776};\nDE            EC=1.2.1.101 {ECO:0000269|PubMed:33372776};\nDE   AltName: Full=FR901483 biosynthesis cluster protein A {ECO:0000303|PubMed:33372776};\nGN   Name=FrzA {ECO:0000303|PubMed:33372776};\nOS   Cladobotryum sp.\nOC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Sordariomycetes;\nOC   Hypocreomycetidae; Hypocreales; Hypocreaceae; Cladobotryum.\nOX   NCBI_TaxID=2040732;\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 18,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8F1L4?format=txt&versions=18)

```json
{
  "evidence_id": "H2",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A7T8F1L4?format=txt&versions=18",
  "source_sha256": "dc244e3d4206d7a97707ec88200b44521e519f3504ebcf6f0cd7d074b3fd2c4b",
  "retrieved_utc": "2026-11-02T04:25:50.375049+00:00",
  "source_locator": "lines 14-22",
  "excerpt": "RN   [1]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, AND\nRP   PATHWAY.\nRC   STRAIN=11231;\nRX   PubMed=33372776; DOI=10.1021/jacs.0c12352;\nRA   Zhang Z., Tamura Y., Tang M., Qiao T., Sato M., Otsu Y., Sasamura S.,\nRA   Taniguchi M., Watanabe K., Tang Y.;\nRT   \"Biosynthesis of the Immunosuppressant (-)-FR901483.\";\nRL   J. Am. Chem. Soc. 143:132-136(2021).\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 18,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8F1L4?format=txt&versions=18)

```json
{
  "evidence_id": "H3",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A7T8F1L4?format=txt&versions=18",
  "source_sha256": "dc244e3d4206d7a97707ec88200b44521e519f3504ebcf6f0cd7d074b3fd2c4b",
  "retrieved_utc": "2026-11-02T04:25:50.375049+00:00",
  "source_locator": "lines 65-66",
  "excerpt": "CC   -!- PATHWAY: Secondary metabolite biosynthesis.\nCC       {ECO:0000269|PubMed:33372776}.\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 18,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 25. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). [Source credits](../THIRD_PARTY_NOTICES.md).
